© 2017 Pharmstandard Ventures
About Us
Pharmstandard Ventures is a Venture Arm within Pharmstandard, JSC, Russia's leading pharmaceutical company.
We were formed in 2013 as Inbio Ventures, and changed our name to Pharmstandard Ventures after corporate restructuring in 2017.
We were formed in 2013 as Inbio Ventures, and changed our name to Pharmstandard Ventures after corporate restructuring in 2017.
About Us
Pharmstandard Ventures is a Venture Arm within Pharmstandard, JSC, Russia's leading pharmaceutical company.
We were formed in 2013 as Inbio Ventures, and changed our name to Pharmstandard Ventures after corporate restructuring in 2017.
We were formed in 2013 as Inbio Ventures, and changed our name to Pharmstandard Ventures after corporate restructuring in 2017.
Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting unmet medical needs or providing dramatic advantages over the competition globally.
Therapeutic Areas of the highest priority are the following:
- Oncology
- Inflammation
- Ophthalmology
- Autoimmunediseases
- Orphangeneticdiseases
- Metabolic Disorders
- Fibrotic diseases
- Cell-based therapy
Stage of development – from preclinical PoC to Phase III
In-licensing / partnering opportunities
With the support of national market leaders, Pharmstandard /Generium group, Pharmstandard Ventures can consider in-licensing / co-development opportunities for the territory of Russia/CIS on case by case basis.
Pharmstandard is leading pharmaceutical company in Russia, dedicated to the development and manufacturing of advanced and affordable pharmaceutical products. Net Sales > $1B, over 250 products launched (Rx and OTC), ∼ 7000 employees, multiple strategic partnerships with Big Pharma.
Generium is a full cycle biotechnology company with its own R&D center and a fully integrated manufacturing facility. The company develops both generic and innovative biopharmaceuticals, seven products are already available for patients in Russia and CIS countries.Generium is the only company in the world, which produces three recombinant coagulation factors (FVII, FVIII and FIX).
Our partners
